UCB Sues Generic-Drug Companies to Block Briviact Copycats

UCB sued generic-drug companies, seeking to block them from selling low-cost versions of the epilepsy drug Briviact.

• Annora, Apotex, Aurobindo, Lupin, Micro Labs, MSN Pharmaceuticals and Zydus are all seeking to sell generic versions of the drug, UCB said in the complaint filed Friday in federal court in Wilmington, Delaware
• The copies would infringe three patents that expire in February 2021, according to the complaint
• Briviact had net sales of 144 million euros ($169 million) in the first six months of the year, UCB said earlier Monday
  • Drug is a “key long-term growth driver for UCB,” according ...